EMBL spin-out extends deal with Japanese pharma

Licensing

Gene Bridges GmbH has announced that Chugai Pharmaceutical Co., Ltd. of Tokyo, Japan, has expanded the commercial license agreement existing since 2005 for the use of its Red/ET recombination technology.

The Red/ET recombination technology, patented in Japan under the title ‘Novel DNA Cloning Method’, is a method for generating targeting vectors, or modifying E. coli chromosomes. “Red/ET is fast becoming the standard DNA engineering technology used in industry and academia worldwide,” claimed Gary Stevens, CEO of Gene Bridges. “Having recently also licensed Red/ET to Daiichi Sankyo and Takeda we are delighted to be signing this amendment to another leading Japanese pharmaceutical company.”

Gene Bridges was founded in 2000 as a spin-out from the European Molecular Biology Laboratory in Heidelberg, Germany.